Graf Akcie SRNE (Sorrento Therapeutics Inc). Diskuze k akciím SRNE. Aktuální informace SRNE.

Základní informace o společnosti Sorrento Therapeutics Inc (Akcie SRNE)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 2.02B
Hodnota podniku (EV) N/A
Tržby 51.024M
EBITDA N/A
Zisk -319.63
Růst v tržbách Q/Q 50.01 %
Růst v tržbách Y/Y 43.57 %
P/E (Cena vůči ziskům) 0.00
Forward P/E 0.62
EV/Sales 39.40
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 39.50
P/FCF N/A
Price/Book 12.20
Účetní hodnota na akcii 0.56
Hotovost na akcii 0.19
FCF vůči ceně -10.97 %
Počet zaměstnanců 502
Tržba na zaměstnance 101.641k
Profit margin -746.41 %
Operating margin -664.55 %
Gross margin 75.14 %
EBIT margin -609.23 %
EBITDA margin -433.92 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst 58.33 %
EPS - Očekávaný růst příští rok -30.30 %
Return on assets -50.53 %
Return on equity -162.21 %
ROIC -48.17 %
ROCE -51.94 %
Dluhy/Equity 2.39
Čistý dluh/EBITDA -3.62
Current ratio 0.86
Quick Ratio 0.85
Volatilita 4.92
Beta 0.36
RSI 41.04
Cílová cena analytiků 26
Známka akcie (dle analytiků) 1.00
Insider ownership 11.16 %
Institutional ownership 27.32 %
Počet akcií 302.951M
Procento shortovaných akcií 17.91 %
Short ratio 9.39 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2009
Země United States

Finanční výsledky akcie SRNE

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$39.986$31.432$21.193$151.856$8.152$4.59
Cost Of Goods Sold$9.94$12.237$7.06$3.945$0.811$1.95
Gross Profit$30.046$19.195$14.133$147.911$7.341$2.64
Research And Development Expenses$111.34$106.879$76.963$55.532$42.175$31.343
SG&A Expenses$116.179$103.557$63.638$38.332$24.219$20.132
Other Operating Income Or Expenses-$11.09$-9.644-$8.121-
Operating Expenses$284.504$290.825$171.618$126.521$104.929$78.595
Operating Income$-244.518$-259.393$-150.425$25.335$-96.777$-74.005
Total Non-Operating Income/Expense$-66.062$-100.183$-63.356$-10.02$31.944$60.245
Pre-Tax Income$-310.58$-359.576$-213.781$15.315$-64.833$-13.76
Income Taxes$-2.014$-0.473$-6.274$-36.038$-0.896$36.314
Income After Taxes$-308.566$-359.103$-207.507$51.353$-63.937$-50.074
Other Income------
Income From Continuous Operations$-314.41$-363.012$-212.526$11.109$-63.937$-50.074
Income From Discontinued Operations------
Net Income$-298.461$-292.068$-203.54$9.132$-60.923$-45.811
EBITDA$-233.511$-248.404$-140.931$32.473$-93.892$-71.635
EBIT$-244.518$-259.393$-150.425$25.335$-96.777$-74.005
Basic Shares Outstanding230133106705037
Shares Outstanding230141106705037
Basic EPS$-1.30$-2.20$-1.92$0.13$-1.21$-1.24
EPS - Earnings Per Share$-1.30$-2.35$-1.92$0.13$-1.21$-1.24
# 2020 2019 2018 2017 2016 2015
Current Ratio0.89380.58672.9140.37621.17834.5677
Long-term Debt / Capital0.3960.85870.51820.02460.35260.0302
Debt/Equity Ratio0.82057.18491.12430.02520.5470.0655
Gross Margin75.141361.068366.687197.402190.051557.5163
Operating Margin-611.509-825.2514-709.786216.6836-1187.156-1612.309
EBIT Margin-611.509-825.2514-709.786216.6836-1187.156-1612.309
EBITDA Margin-583.9819-790.2902-664.988321.3841-1151.766-1560.675
Pre-Tax Profit Margin-776.7218-1143.981-1008.73410.0852-795.3017-299.7821
Net Profit Margin-746.4138-929.2059-960.41146.0136-747.3381-998.061
Asset Turnover0.07460.05640.0340.35180.02030.0134
Inventory Turnover Ratio5.42873.63982.4362---
Receiveable Turnover2.57872.17464.861938.67962.7311.7532
Days Sales In Receivables141.5418167.845275.07369.4365133.6512208.1852
ROE - Return On Equity-223.4122-1108.23-102.42225.3768-73.9139-35.5291
Return On Tangible Equity-1337.8527.2509-206.498411.4174322.7184-43.0189
ROA - Return On Assets-58.6781-65.0989-34.05392.5738-15.9211-14.5768
ROI - Return On Investment-134.9463-156.576-49.35175.2445-47.8538-34.4549
Book Value Per Share0.51120.19521.69692.49221.73.7314
Operating Cash Flow Per Share0.537-0.17830.3563-0.0008-0.2686-0.0616
Free Cash Flow Per Share0.7113-0.27550.4067-0.0205-0.3044-0.1399